| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 32.04% | Morgan Stanley | $14 → $15 | Maintains | Equal-Weight |
| 10/10/2023 | 23.24% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 09/29/2023 | 67.25% | JP Morgan | $17 → $19 | Maintains | Overweight |
| 07/11/2023 | 32.04% | Morgan Stanley | $15 → $15 | Reiterates | Equal-Weight → Equal-Weight |
| 03/28/2023 | 49.65% | B of A Securities | $16 → $17 | Maintains | Buy |
| 03/02/2023 | 49.65% | UBS | $15 → $17 | Maintains | Buy |
| 03/02/2023 | -3.17% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2023 | 40.85% | BTIG | $14 → $16 | Maintains | Buy |
| 11/08/2022 | 32.04% | Morgan Stanley | $14 → $15 | Maintains | Equal-Weight |
| 09/09/2022 | 23.24% | Morgan Stanley | → $14 | Initiates Coverage On | → Equal-Weight |
| 02/24/2022 | 23.24% | SVB Leerink | $16 → $14 | Maintains | Outperform |
| 01/14/2022 | 40.85% | SVB Leerink | $12 → $16 | Upgrades | Market Perform → Outperform |
| 01/13/2022 | 32.04% | Cantor Fitzgerald | $16 → $15 | Maintains | Overweight |
| 11/15/2021 | 40.85% | Stifel | $12 → $16 | Upgrades | Hold → Buy |
| 09/30/2021 | 40.85% | JP Morgan | → $16 | Upgrades | Neutral → Overweight |
| 09/30/2021 | 5.63% | SVB Leerink | $13 → $12 | Maintains | Market Perform |
| 05/27/2021 | — | Needham | Initiates Coverage On | → Hold | |
| 05/21/2021 | 40.85% | UBS | → $16 | Initiates Coverage On | → Buy |
| 04/14/2021 | — | Cantor Fitzgerald | Upgrades | Neutral → Overweight | |
| 03/22/2021 | 14.44% | SVB Leerink | $15 → $13 | Maintains | Market Perform |
| 03/02/2021 | 14.44% | Stifel | → $13 | Initiates Coverage On | → Hold |
| 02/12/2021 | 49.65% | Cantor Fitzgerald | $30 → $17 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 67.25% | JP Morgan | → $19 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 32.04% | SVB Leerink | $30 → $15 | Downgrades | Outperform → Market Perform |
| 12/14/2020 | 164.08% | SVB Leerink | $24 → $30 | Maintains | Outperform |
| 11/11/2020 | 84.86% | Berenberg | → $21 | Initiates Coverage On | → Hold |
| 11/06/2020 | 111.27% | SVB Leerink | $19 → $24 | Maintains | Outperform |
| 08/11/2020 | 76.06% | Citigroup | $15 → $20 | Maintains | Buy |
| 06/17/2020 | 67.25% | BTIG | → $19 | Initiates Coverage On | → Buy |
| 02/04/2020 | 76.06% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 04/05/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 01/30/2019 | 76.06% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 01/17/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 12/18/2018 | 58.45% | Guggenheim | → $18 | Initiates Coverage On | → Buy |
What is the target price for Amicus Therapeutics (FOLD)?
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $15.00 expecting FOLD to rise to within 12 months (a possible 32.04% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amicus Therapeutics (FOLD)?
The latest analyst rating for Amicus Therapeutics (NASDAQ: FOLD) was provided by Morgan Stanley, and Amicus Therapeutics maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Amicus Therapeutics (FOLD) correct?
While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a maintained with a price target of $14.00 to $15.00. The current price Amicus Therapeutics (FOLD) is trading at is $11.36, which is out of the analyst's predicted range.